ERBB2 and salivary duct carcinoma: AR positive adenocarcinomas were similarly to salivary duct carcinoma targeted with ADT therapy in clinical trials, while HER2 amplified tumours demonstrated enhanced sensitivity to T-DM1 therapy [63].